NCT02269358View on ClinicalTrials.gov

Salvage Therapy With High/Low Methotrexate for Loss of Response to Infliximab Dose Escalation

PHASE4CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

October 9, 2018

Study Completion Date

October 9, 2018

Conditions
Crohn's Disease
Interventions
DRUG

METHOTREXATE

Infliximab therapy after escalation. SC methotrexate at 15 mg/m2 , not to exceed 25 mg/m2 per week for 4 weeks. Patients in remission after 4 weeks reduce their dose by halve. patients not in remission will continue the full dose until 12 weeks.

Trial Locations (1)

58100

The E. Wolfson.Medical Center, Holon

All Listed Sponsors
lead

Prof. Arie Levine

OTHER_GOV

NCT02269358 - Salvage Therapy With High/Low Methotrexate for Loss of Response to Infliximab Dose Escalation | Biotech Hunter | Biotech Hunter